Determinants of malaria protective immunity in mice immunized with live sporozoites during trimethoprim-sulfamethoxazole prophylaxis.
journal contributionposted on 09.02.2021, 11:43 by Charlotte V Hobbs, Tejram Sahu, Jillian Neal, Solomon Conteh, Tatiana Voza, William Borkowsky, Jean Langhorne, Patrick E Duffy
HIV and malaria geographically overlap. Trimethoprim-sulfamethoxazole (TMP-SMX) is a drug widely used in HIV-exposed uninfected and infected children in malaria-endemic areas, and is known to have antimalarial effects. Further study in terms of antimalarial impact and effect on development of malaria-specific immunity is therefore essential. Using rodent malaria models, we previously showed that repeated Plasmodium exposure during TMP-SMX administration, or chemoprophylaxis vaccination (CVac), induces CD8 T-cell-dependent preerythrocytic immunity. However, humoral immune responses have been shown to be important in models of preerythrocytic immunity. Herein, we demonstrate that antibody-mediated responses contribute to protective immunity induced by CVac immune sera using TMP-SMX in models of homologous, but not heterologous, parasite species. Clinical studies must account for potential anti-Plasmodium antibody induced during TMP-SMX prophylaxis.